+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Rituximab for steroid-refractory chronic graft-versus-host disease

Rituximab for steroid-refractory chronic graft-versus-host disease

Blood 108(2): 756-762

B cells may be implicated in the pathophysiology of chronic graft-versus-host disease (GVHD), as evidenced by antibody production against sex-mismatched, Y chromosome-encoded minor HLA antigens in association with chronic GVHD. We therefore designed a phase 1/2 study of anti-B-cell therapy with rituximab in steroid-refractory chronic GVHD. Twenty-one patients were treated with 38 cycles of rituximab. Rituximab was tolerated well, and toxicity was limited to infectious events.

(PDF emailed within 0-6 h: $19.90)

Accession: 012522417

Download citation: RISBibTeXText

PMID: 16551963

DOI: 10.1182/blood-2006-01-0233

Related references

Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica 95(11): 1935-1942, 2011

Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 86(6): 875-879, 2008

Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. Biology of Blood and Marrow Transplantation 15(9): 1005-1013, 2009

Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease. Leukemia & Lymphoma 48(3): 623-624, 2007

Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease. International Journal of Hematology 90(2): 253-260, 2009

Pulse Cyclophosphamide for Steroid-Refractory Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation 22(3): S393-S395, 2016

Sirolimus for Treatment of Steroid-Refractory Chronic Graft Versus Host Disease. Blood 100(11): Abstract No 3344, November 16, 2002

Late Onset and Protracted Course of Steroid Refractory Chronic Graft-versus-Host Disease. Case Reports in Hematology 2015: 692175-692175, 2015

Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. British Journal of Haematology 112(3): 820-823, March, 2001

Steroid Refractory Chronic Graft-Versus-Host-Disease: Cost-Effectiveness Analysis. Biology of Blood and Marrow Transplantation, 2018

Infliximab as Treatment for Steroid Refractory Acute and Chronic Graft-Versus-Host Disease. Blood 100(11): Abstract No 5372, November 16, 2002

Topical steroid injection for refractory oral chronic graft-versus-host disease. Japanese Journal of Clinical Hematology 48(11): 1508-1510, 2007

Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease. Haematologica 97(5): 717-722, 2012

Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease. Transfusion and Apheresis Science 30(3): 185-187, 2004

Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation 19(5): 804-811, 2014